Management of high-risk pulmonary embolism in the emergency department: A narrative review

Am J Emerg Med. 2024 May:79:1-11. doi: 10.1016/j.ajem.2024.01.039. Epub 2024 Feb 3.

Abstract

Background: High-risk pulmonary embolism (PE) is a complex, life-threatening condition, and emergency clinicians must be ready to resuscitate and rapidly pursue primary reperfusion therapy. The first-line reperfusion therapy for patients with high-risk PE is systemic thrombolytics (ST). Despite consensus guidelines, only a fraction of eligible patients receive ST for high-risk PE.

Objective: This review provides emergency clinicians with a comprehensive overview of the current evidence regarding the management of high-risk PE with an emphasis on ST and other reperfusion therapies to address the gap between practice and guideline recommendations.

Discussion: High-risk PE is defined as PE that causes hemodynamic instability. The high mortality rate and dynamic pathophysiology of high-risk PE make it challenging to manage. Initial stabilization of the decompensating patient includes vasopressor administration and supplemental oxygen or high-flow nasal cannula. Primary reperfusion therapy should be pursued for those with high-risk PE, and consensus guidelines recommend the use of ST for high-risk PE based on studies demonstrating benefit. Other options for reperfusion include surgical embolectomy and catheter directed interventions.

Conclusions: Emergency clinicians must possess an understanding of high-risk PE including the clinical assessment, pathophysiology, management of hemodynamic instability and respiratory failure, and primary reperfusion therapies.

Keywords: Cardiac arrest; High-risk pulmonary embolism; Massive pulmonary embolism; Pulmonary; Pulmonary embolism; Thrombolytics; Vascular; Venous thromboembolism.

Publication types

  • Review

MeSH terms

  • Embolectomy / adverse effects
  • Emergency Service, Hospital
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Pulmonary Embolism* / etiology
  • Thrombolytic Therapy*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents